Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.30 -6.5%	$1.30	$1.05 ▼ $10.16	$40.90M	1.65	418,129 shs	429,270 shs
BCDA BioCardia	$1.87 -0.5%	$2.13	$1.63 ▼ $4.66	$10.85M	0.81	164,750 shs	53,328 shs
CALC CalciMedica	$2.78 -5.4%	$2.38	$1.42 ▼ $5.97	$38.84M	1.33	47,535 shs	33,812 shs
COEP Coeptis Therapeutics	$13.57 -7.4%	$9.75	$2.31 ▼ $14.70	$47.63M	-0.59	83,368 shs	57,737 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+2.96%	+13.01%	+2.96%	+11.20%	-81.71%
BCDA BioCardia	-2.08%	+11.90%	-15.70%	-4.08%	-43.37%
CALC CalciMedica	+1.03%	+6.52%	-2.33%	+58.06%	-29.79%
COEP Coeptis Therapeutics	+4.87%	+32.46%	+37.17%	+51.66%	+262.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	2.6886 of 5 stars	3.5	3.0	2.3	1.7	0.6
BCDA BioCardia	3.6254 of 5 stars	3.8	5.0	2.4	2.5	0.6
CALC CalciMedica	3.3582 of 5 stars	3.5	5.0	2.4	3.3	0.0
COEP Coeptis Therapeutics	0.5216 of 5 stars	0.0	3.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.57	1,251.65% Upside
BCDA BioCardia	3.50	Strong Buy	$25.00	1,236.90% Upside
CALC CalciMedica	3.00	Buy	$16.00	475.54% Upside
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BCDA, COEP, ACRV, and CALC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/14/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A
BCDA BioCardia	$60K	180.77	N/A	N/A	$0.18 per share	10.39
CALC CalciMedica	N/A	N/A	N/A	N/A	$1.07 per share	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	$1.61 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$80.56M	-$2.25	N/A	N/A	N/A	N/A	-50.78%	-46.08%	N/A
BCDA BioCardia	-$7.95M	-$1.85	N/A	N/A	N/A	N/A	-19,117.42%	-246.92%	N/A
CALC CalciMedica	-$13.70M	-$1.60	N/A	N/A	N/A	N/A	-206.51%	-103.81%	N/A
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-216.96%	-113.00%	N/A

Latest BCDA, COEP, ACRV, and CALC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	COEP Coeptis Therapeutics	N/A	-$1.17	N/A	-$1.17	N/A	$0.20 million
8/13/2025	Q2 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.55	+$0.02	-$0.55	N/A	N/A
8/12/2025	Q2 2025	CALC CalciMedica	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A
8/11/2025	Q2 2025	BCDA BioCardia	-$0.50	-$0.40	+$0.10	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	10.31	10.31
BCDA BioCardia	N/A	0.33	0.33
CALC CalciMedica	1.39	5.45	5.45
COEP Coeptis Therapeutics	0.02	0.82	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
BCDA BioCardia	20.57%
CALC CalciMedica	N/A
COEP Coeptis Therapeutics	13.88%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	8.50%
BCDA BioCardia	20.00%
CALC CalciMedica	41.55%
COEP Coeptis Therapeutics	24.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.46 million	28.78 million	Not Optionable
BCDA BioCardia	40	5.80 million	4.64 million	Optionable
CALC CalciMedica	30	13.97 million	8.17 million	No Data
COEP Coeptis Therapeutics	2	3.51 million	2.66 million	Not Optionable

BCDA, COEP, ACRV, and CALC Headlines

Recent News About These Companies

Coeptis Therapeutics Holdings, Inc. Announces Extinguishment of Convertible Note, Strengthening Capital Structure

July 22, 2025 | quiverquant.comQ

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

July 22, 2025 | globenewswire.com

Coeptis Therapeutics Holdings, Inc. (COEPW) - Yahoo Finance

July 8, 2025 | finance.yahoo.com

Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared - Morningstar

June 27, 2025 | morningstar.comM

Coeptis Therapeutics Files Form S-4 Registration Statement for Proposed Merger with Z Squared Inc. - Nasdaq

June 27, 2025 | nasdaq.com

Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared

June 26, 2025 | globenewswire.com

SNAP Biosciences licenses Monarch’s cell therapy tech

May 29, 2025 | investing.com

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

May 28, 2025 | globenewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders

May 7, 2025 | morningstar.comM

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COEP and PPBI on Behalf of Shareholders

May 1, 2025 | globenewswire.com

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Coeptis Therapeutics Holdings, Inc. - COEP

April 28, 2025 | prnewswire.com

Biopharma Firm Merges With Z Squared to Form Largest Publicly-Listed Dogecoin Miner

April 26, 2025 | news.bitcoin.com

News Explorer — Planned Merger Will Create Publicly Traded Dogecoin Mining Company

April 26, 2025 | decrypt.coD

Coeptis Flops on Merger with Z Squared

April 25, 2025 | baystreet.ca

COEP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Coeptis Therapeutics Holdings, Inc. Is Fair to Shareholders

April 25, 2025 | businesswire.com

Coeptis Therapeutics Holdings, Inc. Enters Definitive Merger Agreement with Z Squared Inc. to Pursue Dogecoin Mining Venture

April 25, 2025 | quiverquant.comQ

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

April 25, 2025 | globenewswire.com

Coeptis Therapeutics announces establishment of new technology hub in India

April 18, 2025 | markets.businessinsider.com

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

April 17, 2025 | globenewswire.com

Coeptis Therapeutics Holdings Inc. Common Stock (COEP) SEC Filings

March 19, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BCDA, COEP, ACRV, and CALC Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.30 -0.09 (-6.47%)

Closing price 04:00 PM Eastern

Extended Trading

$1.35 +0.05 (+3.85%)

As of 04:43 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

BioCardia NASDAQ:BCDA

$1.87 -0.01 (-0.53%)

Closing price 03:59 PM Eastern

Extended Trading

$1.86 -0.01 (-0.53%)

As of 06:48 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

CalciMedica NASDAQ:CALC

$2.78 -0.16 (-5.44%)

Closing price 04:00 PM Eastern

Extended Trading

$2.74 -0.03 (-1.26%)

As of 05:15 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Coeptis Therapeutics NASDAQ:COEP

$13.57 -1.08 (-7.37%)

Closing price 03:59 PM Eastern

Extended Trading

$13.96 +0.39 (+2.84%)

As of 06:19 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time